Imaging of hepatocellular carcinoma patient-derived xenografts using 89Zr-labeled anti-glypican-3 monoclonal antibody

Biomaterials

Volumn 35, Issue 25, 2014, Pages 6964-6971

  Yang, Xiaoyang ^a   Liu, Hongguang ^b   Sun, Chris K ^a   Natarajan, Arutselvan ^b   Hu, Xiang ^b   Wang, Xiaolin ^a   Allegretta, Mark ^c   Guttmann, Ronald D ^c   Gambhir, Sanjiv S ^b   Chua, Mei Sze ^a   Cheng, Zhen ^b   So, Samuel K ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b STANFORD UNIVERSITY   (United States)

^c BioMosaics Incorporated   (United States)

Author keywords

Glypican 3; Hepatocellular carcinoma; Immuno PET; Molecular imaging

Indexed keywords

BIOLOGICAL MATERIALS; BIOLOGICAL MEMBRANES; CELL CULTURE; CHEMICAL DETECTION; DIAGNOSIS; MOLECULAR IMAGING; MONOCLONAL ANTIBODIES; PATIENT TREATMENT; POSITRON EMISSION TOMOGRAPHY; PROBES;

CURRENT DIAGNOSTICS; GLYPICAN-3; HEPATOCARCINOGENESIS; HEPATOCELLULAR CARCINOMA; HIGH CONTRAST IMAGING; IMMUNO-PET; POSITRON EMISSION TOMOGRAPHY (PET); PROSTATE CANCER CELLS;

ZIRCONIUM;

DEFEROXAMINE 1G12 ZR 89; GLYPICAN 3; RADIOPHARMACEUTICAL AGENT; UNCLASSIFIED DRUG; GLYPICAN; MONOCLONAL ANTIBODY; ZIRCONIUM;

ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER SCINTISCANNING; COMPUTER ASSISTED EMISSION TOMOGRAPHY; CONTROLLED STUDY; DIAGNOSTIC IMAGING; DRUG SYNTHESIS; FEMALE; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; INTERNALIZATION; ISOTOPE LABELING; LIVER CELL CARCINOMA; MALE; MOUSE; NONHUMAN; ORTHOTOPIC TRANSPLANTATION; PET-CT SCANNER; PRIORITY JOURNAL; PROSTATE CANCER CELL LINE; TUMOR XENOGRAFT; ANIMAL; CARCINOMA, HEPATOCELLULAR; CHEMISTRY; HEPG2 CELL LINE; LIVER NEOPLASMS; NUDE MOUSE; PATHOLOGY; POSITRON EMISSION TOMOGRAPHY; PROCEDURES; SCID MOUSE; TUMOR CELL LINE; XENOGRAFT;

ANIMALS; ANTIBODIES, MONOCLONAL; CARCINOMA, HEPATOCELLULAR; CELL LINE, TUMOR; DIAGNOSTIC IMAGING; FEMALE; GLYPICANS; HEP G2 CELLS; HETEROGRAFTS; HUMANS; LIVER NEOPLASMS; MALE; MICE; MICE, NUDE; MICE, SCID; POSITRON-EMISSION TOMOGRAPHY; ZIRCONIUM;

EID: 84902085593     PISSN: 01429612     EISSN: 18785905     Source Type: Journal    
DOI: 10.1016/j.biomaterials.2014.04.089     Document Type: Article

References (36)

1. Befeler A.S., Di Bisceglie A.M. Hepatocellular carcinoma: diagnosis and treatment. Gastroenterology 2002, 122:1609-1619.
2. Okuda K. Hepatocellular carcinoma. JHepatol 2000, 32:225-237.
3. Schafer D.F., Sorrell M.F. Hepatocellular carcinoma. Lancet 1999, 353:1253-1257.
4. Bruix J., Llovet J.M. Major achievements in hepatocellular carcinoma. Lancet 2009, 373:614-616.
5. Bruix J., Sherman M. Management of hepatocellular carcinoma. Hepatology 2005, 42:1208-1236. Practice Guidelines Committee AAftSoLD.
6. Massarweh N.N., Park J.O., Farjah F., Yeung R.S., Symons R.G., Vaughan T.L., et al. Trends in the utilization and impact of radiofrequency ablation for hepatocellular carcinoma. JAm Coll Surg 2010, 210:441-448.
7. Murakami T., Kim T., Oi H., Nakamura H., Igarashi H., Matsushita M., et al. Detectability of hypervascular hepatocellular carcinoma by arterial phase images of MR and spiral CT. Acta Radiol 1995, 36:372-376.
8. Coston W.M., Loera S., Lau S.K., Ishizawa S., Jiang Z., Wu C.L., et al. Distinction of hepatocellular carcinoma from benign hepatic mimickers using glypican-3 and CD34 immunohistochemistry. Am J Surg Pathol 2008, 32:433-434.
9. Gambhir S.S. Molecular imaging of cancer with positron emission tomography. Nat Rev Cancer 2002, 2:683-693.
10. Weissleder R. Scaling down imaging: molecular mapping of cancer in mice. Nat Rev Cancer 2002, 2:11-18.
11. Knowles S.M., Wu A.M. Advances in immuno-positron emission tomography: antibodies for molecular imaging in oncology. JClin Oncol 2012, 30:3884-3892.
12. Orlova A., Tolmachev V., Pehrson R., Lindborg M., Tran T., Sandstrom M., et al. Synthetic affibody molecules: a novel class of affinity ligands for molecular imaging of HER2-expressing malignant tumors. Cancer Res 2007, 67:2178-2186.
13. Wu A.M. Antibodies and antimatter: the resurgence of immuno-PET. JNucl Med 2009, 50:2-5.
14. Fletcher J.W., Djulbegovic B., Soares H.P., Siegel B.A., Lowe V.J., Lyman G.H., et al. Recommendations on the use of 18F-FDG PET in oncology. JNucl Med 2008, 49:480-508.
15. Weiner L.M., Surana R., Wang S. Monoclonal antibodies: versatile platforms for cancer immunotherapy. Nat Rev Immunol 2010, 10:317-327.
16. Wu A.M., Senter P.D. Arming antibodies: prospects and challenges for immunoconjugates. Nat Biotechnol 2005, 23:1137-1146.
17. Sogawa C., Tsuji A.B., Yoshida C., Inubushi M., Furukawa T., Koizumi M., et al. Novel human monoclonal antibody against epidermal growth factor receptor as an imaging probe for hepatocellular carcinoma. Nucl Med Commun 2012, 33:719-725.
18. Zhao P., Yang X., Qi S., Liu H., Jiang H., Hoppmann S., et al. Molecular imaging of hepatocellular carcinoma xenografts with epidermal growth factor receptor targeted affibody probes. Biomed Res Int 2013, 2013:759057.
19. Filmus J. Glypicans in growth control and cancer. Glycobiology 2001, 11:19R-23R.
20. Capurro M., Wanless I.R., Sherman M., Deboer G., Shi W., Miyoshi E., et al. Glypican-3: a novel serum and histochemical marker for hepatocellular carcinoma. Gastroenterology 2003, 125:89-97.
21. Hsu H.C., Cheng W., Lai P.L. Cloning and expression of a developmentally regulated transcript MXR7 in hepatocellular carcinoma: biological significance and temporospatial distribution. Cancer Res 1997, 57:5179-5184.
22. Nakatsura T., Yoshitake Y., Senju S., Monji M., Komori H., Motomura Y., et al. Glypican-3, overexpressed specifically in human hepatocellular carcinoma, is a novel tumor marker. Biochem Biophys Res Commun 2003, 306:16-25.
23. Shirakawa H., Kuronuma T., Nishimura Y., Hasebe T., Nakano M., Gotohda N., et al. Glypican-3 is a useful diagnostic marker for a component of hepatocellular carcinoma in human liver cancer. Int J Oncol 2009, 34:649-656.
24. Wang X.Y., Degos F., Dubois S., Tessiore S., Allegretta M., Guttmann R.D., et al. Glypican-3 expression in hepatocellular tumors: diagnostic value for preneoplastic lesions and hepatocellular carcinomas. Hum Pathol 2006, 37:1435-1441.
25. Di Tommaso L., Franchi G., Park Y.N., Fiamengo B., Destro A., Morenghi E., et al. Diagnostic value of HSP70, glypican 3, and glutamine synthetase in hepatocellular nodules in cirrhosis. Hepatology 2007, 45:725-734.
26. Wang H.L., Anatelli F., Zhai Q.J., Adley B., Chuang S.T., Yang X.J. Glypican-3 as a useful diagnostic marker that distinguishes hepatocellular carcinoma from benign hepatocellular mass lesions. Arch Pathol Lab Med 2008, 132:1723-1728.
27. Natarajan A., Habte F., Gambhir S.S. Development of a novel long-lived immunoPET tracer for monitoring lymphoma therapy in a humanized transgenic mouse model. Bioconjug Chem 2012, 23:1221-1229.
28. Vosjan M.J., Perk L.R., Visser G.W., Budde M., Jurek P., Kiefer G.E., et al. Conjugation and radiolabeling of monoclonal antibodies with zirconium-89 for PET imaging using the bifunctional chelate p-isothiocyanatobenzyl-desferrioxamine. Nat Protoc 2010, 5:739-743.
29. Sun C.K., Chua M.S., He J., So S.K. Suppression of glypican 3 inhibits growth of hepatocellular carcinoma cells through up-regulation of TGF-beta2. Neoplasia 2011, 13:735-747.
30. Butler J.E., Spradling J.E., Suter M., Dierks S.E., Heyermann H., Peterman J.H. The immunochemistry of sandwich ELISAs - I. The binding characteristics of immunoglobulins to monoclonal and polyclonal capture antibodies adsorbed on plastic and their detection by symmetrical and asymmetrical antibody-enzyme conjugates. Mol Immunol 1986, 23:971-982.
31. Khan M.A., Combs C.S., Brunt E.M., Lowe V.J., Wolverson M.K., Solomon H., et al. Positron emission tomography scanning in the evaluation of hepatocellular carcinoma. JHepatol 2000, 32:792-797.
32. Yoshimoto M., Waki A., Yonekura Y., Sadato N., Murata T., Omata N., et al. Characterization of acetate metabolism in tumor cells in relation to cell proliferation: acetate metabolism in tumor cells. Nucl Med Biol 2001, 28:117-122.
33. McCabe K.E., Wu A.M. Positive progress in immunoPET - not just a coincidence. Cancer Biother Radiopharm 2010, 25:253-261.
34. Li Y., Chen Z., Li F., Wang J., Zhang Z. Preparation and invitro studies of MRI-specific superparamagnetic iron oxide antiGPC3 probe for hepatocellular carcinoma. Int J Nanomed 2012, 7:4593-4611.
35. Park J.O., Stephen Z., Sun C., Veiseh O., Kievit F.M., Fang C., et al. Glypican-3 targeting of liver cancer cells using multifunctional nanoparticles. Mol Imaging 2011, 10:69-77.
36. Dijkers E.C., Oude Munnink T.H., Kosterink J.G., Brouwers A.H., Jager P.L., de Jong J.R., et al. Biodistribution of 89Zr-trastuzumab and PET imaging of HER2-positive lesions in patients with metastatic breast cancer. Clin Pharmacol Ther 2010, 87:586-592.